GFS
RGLS

GYL Financial Synergies’s Regulus Therapeutics RGLS Stock Holding History

GYL Financial Synergies’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,400
Closed -$10K – 206
2022
Q1 		$10K Sell
3,400
-700
-17% -$1.82K ﹤0.01% 203
2021
Q4 		$13K Hold
4,100
– – ﹤0.01% 209
2021
Q3 		$28K Hold
4,100
– – 0.01% 188
2021
Q2 		$33K Sell
4,100
-1,038
-20% -$11.6K 0.02% 183
2021
Q1 		$80K Hold
5,138
– – 0.04% 177
2020
Q4 		$69K Buy
+5,138
New +$37.7K 0.04% 170

Other funds holding RGLS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

GYL Financial Synergies's RGLS Position: Q2 2022 in Review

GYL Financial Synergies sold out of Regulus Therapeutics (RGLS) in Q2 2022, closing a stake of 3,400 shares — an estimated $10K sold.

GYL Financial Synergies first reported a position in RGLS in Q4 2020 and held it in 6 quarters. The position peaked at $80K in Q1 2021. 27 funds tracked by Wall St. Rank hold RGLS as of Q2 2022.

  • GYL Financial Synergies reported no remaining Regulus Therapeutics position as of Q2 2022 after selling out during the quarter.
  • GYL Financial Synergies sold 3,400 Regulus Therapeutics shares in Q2 2022, an estimated $10K.
  • GYL Financial Synergies first reported a position in Regulus Therapeutics in Q4 2020 and held it in 6 quarters.
  • GYL Financial Synergies's Regulus Therapeutics position peaked at $80K in Q1 2021.
  • 27 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2022.

Based on GYL Financial Synergies's 13F filing for Q2 2022, filed 1 Aug 2022.